Exact Sciences And Mayo Clinic Initiate 150,000 Patient, 7-Year Study To Evaluate Real-World Impact Of Cologuard(R)

Data from Prospective, Observational Study will Strengthen Clinical Evidence and Support Continued Cologuard Adoption MADISON, Wis., Oct. 14, 2019 -- (Healthcare Sales & Marketing Network) -- (NASDAQ: EXAS) – Exact Sciences Corp. today announced that, ... Diagnostics, Oncology, Gastroenterology Exact Sciences, Cologuard, colorectal cancer screening, Voyage study
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news